A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
To assess the safety, tolerability, PK and preliminary efficacy of CD-001 in patients with advanced solid tumors. and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Advanced Solid Tumors
DRUG: CD-001
Number of Participants with Dose Limiting Toxicities (DLTs), 28 days|Incidence of AE and serious adverse events (SAE), According to National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v5.0), Up to 3 Years|The recommended dose for expansion (RDE) and/ or maximum tolerated dose (MTD) of CD-001 monotherapy, Up to 3 Years
Maximum Observed Plasma Concentration (Cmax) of CD-001, Up to 3 Years|Time to Achieve Cmax (Tmax) of CD-001, Up to 3 Years|Area Under the Plasma Concentration-time Curve (AUC) of CD-001, Up to 3 Years|Objective Response (OR), Up to 3 Years|Duration of Response (DOR), Up to 3 Years|Progression-Free Survival (PFS), Up to 1 Years|Disease Control Rate (DCR), Up to 3 Years|Overall Survival (OS), Up to 3 Years|Frequency of anti-drug antibody (ADA) to CD-001, Up to 3 Years
To assess the safety, tolerability, PK and preliminary efficacy of CD-001 in patients with advanced solid tumors. and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).